352 related articles for article (PubMed ID: 23054651)
1. P2Y12 receptor: platelet thrombus formation and medical interventions.
Moheimani F; Jackson DE
Int J Hematol; 2012 Nov; 96(5):572-87. PubMed ID: 23054651
[TBL] [Abstract][Full Text] [Related]
2. Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.
Kuijpers MJ; Megens RT; Nikookhesal E; Feijge MA; De Mey JG; oude Egbrink MG; van Giezen JJ; Heemskerk JW
Thromb Haemost; 2011 Dec; 106(6):1179-88. PubMed ID: 22071958
[TBL] [Abstract][Full Text] [Related]
3. Thrombus remodelling by reversible and irreversible P2Y
Tunströmer K; Faxälv L; Larsson P; Lindahl TL; Boknäs N
Platelets; 2023 Dec; 34(1):2157805. PubMed ID: 36631918
[TBL] [Abstract][Full Text] [Related]
4. Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.
Speich HE; Bhal V; Houser KH; Caughran AT; Lands LT; Houng AK; Bäckstrom J; Enerbäck M; Reed GL; Jennings LK
J Cardiovasc Pharmacol; 2014 Jun; 63(6):520-7. PubMed ID: 24477045
[TBL] [Abstract][Full Text] [Related]
5. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.
Ferri N; Corsini A; Bellosta S
Drugs; 2013 Oct; 73(15):1681-709. PubMed ID: 24114622
[TBL] [Abstract][Full Text] [Related]
7. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
8. The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Cattaneo M
Blood; 2011 Feb; 117(7):2102-12. PubMed ID: 20966167
[TBL] [Abstract][Full Text] [Related]
9. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
10. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
11. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.
Conley PB; Delaney SM
Curr Opin Hematol; 2003 Sep; 10(5):333-8. PubMed ID: 12913786
[TBL] [Abstract][Full Text] [Related]
12. Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.
Högberg C; Gidlöf O; Deflorian F; Jacobson KA; Abdelrahman A; Müller CE; Olde B; Erlinge D
Thromb Haemost; 2012 Jul; 108(1):119-32. PubMed ID: 22628078
[TBL] [Abstract][Full Text] [Related]
13. Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes.
Balduini A; Di Buduo CA; Malara A; Lecchi A; Rebuzzini P; Currao M; Pallotta I; Jakubowski JA; Cattaneo M
Haematologica; 2012 Nov; 97(11):1657-65. PubMed ID: 22689668
[TBL] [Abstract][Full Text] [Related]
14. Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
Mshelbwala FS; Hugenberg DW; Kreutz RP
J Thromb Thrombolysis; 2020 Oct; 50(3):619-627. PubMed ID: 32152791
[TBL] [Abstract][Full Text] [Related]
15. Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts.
Yang XM; Liu Y; Cui L; Yang X; Liu Y; Tandon N; Kambayashi J; Downey JM; Cohen MV
J Cardiovasc Pharmacol Ther; 2013 May; 18(3):251-62. PubMed ID: 23233653
[TBL] [Abstract][Full Text] [Related]
16. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Savi P; Herbert JM
Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
[TBL] [Abstract][Full Text] [Related]
18. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
Judge HM; Buckland RJ; Jakubowski JA; Storey RF
Platelets; 2016; 27(3):191-5. PubMed ID: 26270719
[TBL] [Abstract][Full Text] [Related]
19. P2Y
Hensch NR; Karim ZA; Pineda J; Mercado N; Alshbool FZ; Khasawneh FT
Biochem Biophys Res Commun; 2017 Nov; 493(2):1069-1074. PubMed ID: 28928091
[TBL] [Abstract][Full Text] [Related]
20. P2Y12 receptors: structure and function.
Cattaneo M
J Thromb Haemost; 2015 Jun; 13 Suppl 1():S10-6. PubMed ID: 26149010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
